Novo Nordisk adds e-books to patient support program

Share this article:
Novo Nordisk adds e-books to patient support program
Novo Nordisk adds e-books to patient support program
Novo Nordisk is getting in on the boom in electronic publishing with a series of e-books available through its Cornerstones4Care patient support program.

The free five-volume series, compatible with all major e-readers and downloadable at Cornerstones4Care.com, covers topics like carb counting, meal planning and maintaining a blood sugar diary.

The company cited Association of American Publishers data showing that as of February, e-books were the top-selling format among all categories of trade publishing, with sales on the rise.

“With an increasing demand for e-books, we saw an opportunity to share our existing diabetes education book series in a new and innovative format that meets the changing technology needs of today's patient,” said corporate VP, diabetes marketing Camille Lee. “By broadening the availability of the educational series, we hope that more patients willhave access to the resources they need to better manage their diabetes.”
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...